‘Triple-G’ Weight Loss Drug Update: Even on the Lowest Dose, Trial Patients Lost 12.7% of Their Weight
4 Articles
4 Articles
New York Post
BizToc‘Triple-G’ weight loss drug update: Even on the lowest dose, trial patients lost 12.7% of their weight
The drug, the first of its kind to target three metabolic receptors (GLP-1, GIP, and glucagon), is nearing the end of clinical trials and is expected to be submitted to the FDA for approval early next year.
Results of a clinical trial of retatrotide show that the highest dose of this triple-drug weight loss drug produced an average weight loss of 25 percent after 80 weeks. The post The most powerful weight loss drug in clinical trial caused a 25-30 percent weight loss appeared first on Digiato.
Retatrutide Delivers More Than 30% Weight Loss in 104-Week Obesity Trial: What the Latest Data Show
A new obesity drug candidate is generating major attention after delivering average weight loss of more than 30% in a long-term clinical-trial extension. The drug is retatrutide, an experimental once-weekly injection being developed by Eli Lilly. In a Phase 3 obesity study, people receiving the highest dose lost an average of 28.3% of their body […]
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
